View
213
Download
0
Category
Tags:
Preview:
Citation preview
The Mediterranean School of Oncology
43th course
“Highlights in the management of colorectal cancer”
Rome, 1-2 February 2007
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
The Mediterranean School of Oncology
An educational program of:
Bologna
Chieti-Pescara
Ferrara
Catanzaro Palermo
Roma La Sapienza
Napoli Federico II
Perugia
Ancona
Teramo
L’Aquila
A Consortium among 14 Italian Universities
Foggia
Messina
CARCINOMA DEL COLON-RETTOSCENARIO GLOBALE
2a causa di morte per cancro nei paesi occidentali!
• ~1,000,000 nuovi casi ~ 500,000 decessi/anno
Alla diagnosi:
• 70-80% malattia localizata, resecabile• 50% stadio II • 35% stadio III
• ~40% (~400,000/anno) ripresa di malattia dopo chirurgia potenzialmente curativa
5-FU
Infusionecontinua
Levamisole LD leucovorin
HD leucovorin
Bolus
Anni ’90: ottimizzazione del 5-FU
Sopravvivenza mediana CRC metastatico, Ia linea
Best supportive care
0 6 12 18 24
Median overall survival (months)
~4–6 months
12–14 months5-FU/LV
19–20 monthsFOLFOX4 or CAPEOX
~15–16 monthsIFL or FOLFIRI
20.6 monthsFOLFOX6 FOLFIRI
18.3 months5-FU/LV +
bevacizumab
25.1 monthsIFL + BV OX
20.3 monthsIFL + bevacizumab
Nel 2007, cosa si può attendere un paziente affetto da carcinoma metastatico del colon-retto?
Soparvvivenza globale :24-26+ mesi
Risposte oggettive :50-70%
Tempo alla progressione :8-11+ mesi
Oltre la I linea
Ia lineaFOLFOX + Bevacizumab
IIIa lineaCetuximab +Irinotecan
IIa lineaIrinotecan + 5-FU(Bevacizumab)
Va lineaFOLFOX + Cetuximab
IVa lineaCetuximab + Bevacizumab+ Irinotecan
VIa lineaFOLFOX + Cetuximab +Bevacizumab
VIIa lineaXX +YY
………….………….
Come identificare i pazienti R e NR alla terapia?
50
100
0
25
75
CRC – Criteri di selezione usuali
100 pazienti trattati con CTdopo 5 anni:
70 sono viventi anche senza CT (o-treated)
20 sono deceduti nonostante la CT
Usando il profilo d’espressione genica
Only 22.5% of pts will be overtreated
Patient goes to
Familiy doctor/health center Population-based screening
Investigations &diagnostic testing
Cancer diagnosed Cancer not diagnosed
Treatment Palliative care
Continuing treatment
Follow-up Relapse Terminal care
Long-term survival BereavementCure
Two classes:
1. Foreign students (in English);
2. Italian residents
All courses are accredited for CME by Ministero della Salute, Italy or/and ESMO
2000 2002 2003 2004
2
4
6
8
10Courses/year
Students/year
200
500
300
400
600
0 0
By December 2006:
42 courses>2200 students
2001 2005 2006
Scholarships
Available to candidates <30 years of age.
To apply for a scholarship:
• a brief curriculum vitae;• a letter of presentation from an authorised officer at the institute of affiliation.
For information:
www. unich.it/mso.cinbo
MSO - 2007 Course Calendar
1-2 February :Highlights in the management of colorectal cancer (E)
16-17 February :Tumori del rene e melanoma: progressi della ricerca traslazionale e clinica
19-20 March :Cardiotossicità da farmaci antitumorali: basi genetiche, diagnosi,
prevenzione e terapia
18-19 April :Highlights in the management of breast cancer (E)
25-26 May :Presente e futuro della terapia del dolore neuropatico in oncologia
8-9 June :Personalized diagnostic and therapeutic strategies in oncology (E)
20-21 July :Sessualità e cancro
5-6 October :I tumori dell’ovaio 26-27 October :New oncology drugs pipeline update: from bench to bedside (E) 23-24 November :Controversie in oncologia
(E) Courses in English
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
A MSO/CINBO’s pilot project
The “Formazione a Distanza inOncologia” (FADO) Program
FADO Program
Teaching is made via satellite technology.
Designed to build or enhance professional knowledge, skills, and leadership in oncology and related disciplines through distance/online education & training.
Target audience
1. Residents in medical oncology;
2. Ph.D. students (Dottorato di Ricerca) in oncology and related disciplines
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
FADO - Partners
Technologies & services:
Organization & management:
QuickTime™ e undecompressore TIFF (LZW)
sono necessari per visualizzare quest'immagine.
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
A MSO/CINBO’s pilot project
The Mediterranean Task Forcefor Cancer Control (MTCC)
• courses in modular print format• videoconferences;• lectures-seminars-lessons;
To provide a forum for
“distance learning discussion among CINBO member Universities and selected medical Institutions within the mediterranean area”
MTCC“An innovative project to raise awarenessabout cancer prevention and early detection via satellite technology”
Algeria Croatia Egypt France Greece
Italy Jordan Lebanon Lybia Morocco
Portugal Syria Slovenia Spain Tunisia Turkey
Palestine
1st Meeting of the Mediterranean Task Force for Cancer Prevention and Early Detection
October 4th, 2005Taormina, Italy
With the participation of delegates from:
Albania
Recommended